Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

77.47 -0.46 (-0.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Astrazeneca Plc ADR

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
47 48 Next >
Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021
Upgrades For CarMax Inc (NYSE: 
Via Benzinga
The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Daré
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Acadia Announces Positive Phase 3 Data For Trofinetide In Rett Syndrome... 
Via Benzinga
Ionis, AstraZeneca Ink Licensing Pact For Eplontersen In Protein Misfolding Disorder
Ionis Pharmaceuticals Inc (NASDAQ: IONS) has entered into a strategic collaboration agreement with AstraZeneca Plc (NASDAQ: AZN) to develop and... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Higher Following Monday's Rally
Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones jumped around 650 points in the previous session. Investors are awaiting earnings... 
Via Benzinga
Topics Stocks
Exposures US Equities
Johnson & Johnson Booster COVID-19 Shot Shows Encouraging Action After Pfizer/BioNTech Jab
Johnson & Johnson (NYSE: JNJ) announced preliminary results from an independent study, including a subset of the Janssen-sponsored COV2008 study participants.... 
Via Benzinga
Exposures COVID-19
Here's Why AstraZeneca Stock Could Help Make You Rich
The pharmaceutical is a high-quality dividend stock that offers investors tremendous growth at a reasonable price. 
Via The Motley Fool
Could Moderna and AstraZeneca's mRNA Heart Failure Drug Candidate Be a Winner?
Yes, but it could take a while. 
Via The Motley Fool
Exposures COVID-19
Charms Of China
Today the global stock market rout was pretty awful. 
Via Talk Markets
Valneva's COVID-19 Shot Fails As Booster In Pfizer/BioNTech Vaccinated Population
Valneva SE (NASDAQ: VALN) has responded to data published from the U.K COV-Boost COVID-19 vaccine trial that investigated the reactogenicity and immunogenicity of... 
Via Benzinga
Exposures COVID-19
The 'Highly Mutated Virus' Signals A Need For Annual Shots: BioNTech CEO
The omicron variant signals a need for annual Covid shots, BioNTech's CEO said. 
Via Investor's Business Daily
The Implications Behind Genetron Health's Latest Earnings Report
Image provided by Mentor Finance Genetron Holdings Limited (NASDAQ: GTH) recently announced its latest fiscal report, elaborating its progress in the oncology genetic testing... 
Via Benzinga
AstraZeneca Blocks SOBI's $8B Buyout, Advent Withdraws The Bid - Report
AstraZeneca Plc (NASDAQ: AZN) blocked an $8 billion takeover of Swedish Orphan Biovitrum AB (OTC: BIOVF) by withholding its 8% stake in SOBI from a buyout offer by... 
Via Benzinga
Thursday Markets Overview
Today we are seeing an across-the-board rise in stock prices on hopes for lower inflation and Omicron jabbing. 
Via Talk Markets
Possible New Links Identified With AstraZeneca COVID-19 Shot, Blood Clots
Scientists have identified a possible reason the AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine may cause blood clots after the use of the shot was limited to... 
Via Benzinga
Exposures COVID-19
Is High Pressure Good for Drug Development?
Picture credit: National Cancer Institute The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a... 
Via Benzinga
Breakthrough Cancer Therapy? This Biotech Shares Preclinical Data and Ambitious Plans
Photo by National Cancer Institute on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a... 
Via Benzinga
Have the Markets Overreacted to Omicron?
The emergence of the “omicron” variant of the novel coronavirus caused a major stir on Wall Street last week. But was it an overreaction? 
Via InvestorPlace
Exposures COVID-19
7 Drug Stocks to Buy Now While They’re Still on Sale
Covid-19 stocks soared to unsustainable highs as investors ignored drug stocks with a deep pipeline of products for the decade ahead. 
Via InvestorPlace
Topics Supply Chain
Exposures COVID-19 Supply Chain
The Daily Biotech Pulse: Cumberland Jumps On FDA Nod, Regeneron Says Antibody Treatment May Be Less Effective Against Omicron, ImmunoGen Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Cumberland Gets FDA Approval For IV-Delivered Ibuprofen For Use In Pre-... 
Via Benzinga
Exposures Product Safety
AstraZeneca-Merck's Lynparza Under FDA Priority Review For Breast Cancer Setting
The FDA has granted priority review for AstraZeneca Plc's (NASDAQ: AZN) supplemental marketing application for Lynparza (olaparib) for breast cancer.... 
Via Benzinga
Exposures Product Safety
Novavax Is a Buy Based on Its Outlook, But Not for the Long Haul
As the Novavax vaccine becomes approved by more and more countries, NVAX stock will likely climb in the near-to-medium term. 
Via InvestorPlace
Exposures COVID-19
Adagio shares soar on antibody potential against new COVID variant omicron
Stifel analyst Stephen Willey believes vaccines alone are unlikely to sufficiently address the COVID-19 pandemic. 
Via Talk Markets
Exposures COVID-19
3 Pharma Stocks Morgan Stanley Says Will Be Omicron Variant Beneficiaries
The news of a new variant of the coronavirus Friday sent financial markets into a tailspin. The adversity could present an opportunity for a h... 
Via Benzinga
Exposures COVID-19
Vaccine Stocks Ask The Unthinkable: What Happens If Today's Covid Shots Fail?
Smaller companies are working on next-generation approaches to Covid treatment. 
Via Investor's Business Daily
These Biotech Companies Are Attempting to Use Improved Antibody Technology in the Fight To Eradicate COVID-19
Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of... 
Via Benzinga
Got $5,000? These 2 Stocks Could Be Bargain Buys in 2022
Both of these businesses could be in much better shape a year from now. 
Via The Motley Fool
Pfizer's COVID-19 Franchise Could Push Revenue Past $100B In 2022: Analyst
Pfizer, Inc. (NYSE:PFE) found huge success with its COVID-19 ... 
Via Benzinga
Exposures COVID-19
AstraZeneca Decides It's OK to Make Money From the Pandemic
Lackluster third-quarter results may have contributed to the decision to stop selling its COVID-19 vaccine at no profit. 
Via The Motley Fool
Exposures COVID-19
EU Says Decision On J&J COVID-19 Booster Shot Expected 'Within Weeks'
The European Medicines Agency (EMA) said it was evaluating data on booster doses of the COVID-19 vaccine by Johnson & Johnson (NYSE: JNJ). The CHMP will recommend... 
Via Benzinga
Exposures COVID-19
Friday Markets Coverage
Today markets are suffering alongside Austria which locked down against Covid-19 again. 
Via Talk Markets
Exposures COVID-19
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
47 48 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.